SCIENTIFIC PUBLICATIONS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
AACR Annual Meeting 2026 – Presentation and Posters
STRO-004, a Next-Generation Tissue Factor (TF)-Targeted DAR8-Exatecan ADC, Demonstrates Superior Efficacy Across TF-Expressing Solid Tumors in a Comprehensive Single-Mouse PDX Trial Presenter: Genevive Hernandez, Ph.D.Phase 1 open-label study to evaluate safety,...
16th Annual World ADC London Summit – Presentation
Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms Presenter: Hans-Peter Gerber, Ph.D., Chief Scientific Officer
Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting – Poster Presentation
Next-Generation Immunostimulatory Antibody-Drug Conjugates (iADCs) Combine Tumor Cell Killing with Immune Activation to Induce Durable Antitumor Immunity
16th Annual World ADC San Diego – Presentations
Showcasing Development of Site-Specific, High-DAR Dual-Payload ADCs Presenter: Daniel Calarese, Ph.D.Developing Next-Generation Immunostimulatory Dual Payload ADCs to Enhance Therapeutic Index & Tackle Patient Resistance Presenter: Gang Yin, Ph.D.Laying Out...
Sutro R&D Day – Presentation
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
SOUTH SAN FRANCISCO, Calif., November 5, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research &...
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., November 3, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC...
Whitepaper: The Power of Partnership in Advancing Innovation
Sutro Biopharma and Boehringer Ingelheim collaborate to scale-up a novel cell-free technology platform to produce ADCs. Explore how cell-free ADC manufacturing is shaping cancer therapy.